Tarsus Pharmaceuticals, Inc.
TARS
$46.47
$2.906.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -115.55M | -134.34M | -150.07M | -148.21M | -135.89M |
| Total Depreciation and Amortization | 1.23M | 1.14M | 1.10M | 1.04M | 877.00K |
| Total Amortization of Deferred Charges | 482.00K | 455.00K | 427.00K | 418.00K | 385.00K |
| Total Other Non-Cash Items | 26.98M | 25.80M | 24.39M | 20.31M | 16.83M |
| Change in Net Operating Assets | 3.84M | 6.76M | 261.00K | -6.88M | 306.00K |
| Cash from Operations | -83.03M | -100.18M | -123.89M | -133.31M | -117.49M |
| Capital Expenditure | -1.57M | -1.50M | -1.59M | -1.34M | -1.50M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -197.63M | -120.28M | -75.94M | 28.42M | 142.11M |
| Cash from Investing | -199.20M | -121.77M | -77.53M | 27.09M | 140.60M |
| Total Debt Issued | 75.00M | 75.00M | 80.00M | 5.00M | 10.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 112.38M | 129.21M | 228.42M | 228.93M | 120.18M |
| Repurchase of Common Stock | -6.69M | -6.69M | -6.69M | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -26.04M | -26.04M | -26.00M | -- | -- |
| Cash from Financing | 154.66M | 171.49M | 275.74M | 233.93M | 130.18M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -127.57M | -50.46M | 74.32M | 127.71M | 153.29M |
